- Acronyme: PharmaBrain
- Registration number: CZ.02.1.01/0.0/0.0/16_025/0007444
- Brief description: The main objective of the project of the PharmaBrain centre is to form a research platform for the study of neuropsychiatric, neurodevelopmental
and neurodegenerative disorders, which will contribute to building capacities and strengthening long-term co-operation of research organisations, and improving the
possibilities for co-operation with the application sphere in the field of research and development of “CNS drugs” (substances influencing the nervous system),
diagnostic aids and innovative therapeutic procedures. The main contribution shall be benefits of a non-monetary value, leading to the development of knowledge
concerning pathophysiological disorders of the central nervous system (CNS), which represent one of the most pronounced and rapidly increasing economic and social
costs in modern society. These disorders and their consequences frequently reduce the quality of life of the affected individual, and their treatment, together
with compensation of the consequences of the disorder, at the same time places a significant burden on the resources of health and social care. And benefits in
the field of improving the organisation of research on a national level and benefits in terms of economic-commercial possibilities for establishing spin-off
companies on the basis of proof-of-concept activities and intensifying co-operation with domestic and foreign subjects in the application sphere.
- Realisation schedule: 1. 1. 2018 - 31. 12. 2022
- Principal investigator: RNDr. Eva Kudová, Ph.D.
- Beneficiary: National Institute of Mental Health
- Partners with financial contribution:
Institute of Physiology of the CAS
University of Hradec Králové
Charles University (Third Faculty of Medicine)
Institute of Organic Chemistry and Biochemistry of the CAS
- Agreement on Partnership (with financial contribution) (in Czech)
- This project is co-financed by the European Union